Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now people ccan know why I believe AMRS is going to 1.00 or more..analyst set those prices, not me and they are much higher than the 1.00 I said.....
Great news.....I expect a slew of these beginning next week..you can just feel it in the air
NOW WHAT DO YOU THINK ANALYST WILL SAY NEXT WEEK AND BEYOND TO THEIR CLIENTS.....AND I WOULD EXPECT SOME MORE ANALYST TO INITIATE COVERAGE OF AMRS..............
And again
The Rise of Organic Manufacturing: Ginkgo, Amyris, Genomatica’s circle of innovation is a trend to watch
September 29, 2016 | Jim Lane
Tweet
3
Share
Mail
61
Share
bd-ts-093016-organic-manufacturing-smThe factories of old — a technological wave that swept in with the Industrial Revolution — these were inorganic manufacturing centers, and they are now the wave of the past.
They used a suite of lifeless fossil ingredients and mechanical, lifeless manufacturing techniques. They might have been made fast through computers, sensors and robotics, but they were not alive. Products were made, not grown.
But today a wave of companies have taken something important from agriculture — the concept of growing something useful by using life itself — using biology. And they are introducing a wave of organic manufacturing that is now just beginning to take shape.
The change may not yet be obvious. Companies are still putting steel in the ground, and using advanced robotics and analytics to add speed and value to the old ways. But the change is underway — consider in the far future that everything about manufacturing will be living, from life, organic. The inputs, the processes, the very walls of the feremnters themselves and every system in the plant.
Out with the old, in with the new
Out with the old inorganic feedstocks like coal, oil and gas. In with the new feedsocks like woods, grasses, fibers and sugars. Out with the old inorganic catalysts, and in with the new ones like enzymes. Out with the old digital sensors and in with new skin-like sensors based on the way organisms sense light, heat, sound, pressure, velocity and more. Out with the old manufacturing trains made with steel, glass and plastic, and in with new organic materials with better functional properties and physical flexibility. Out with the old inorganic multi-step, anallog chemical transformations, and in with one-step transformations achieved by a new generation of designer microorganisms.
Based in microbes, the new organic manufacturing offers the promise of a billion manufacturing sites in a teaspoon — rolled up into giant industrial symbiosis that is sustainable, affordable, and reliable and can be adjusted to account for new innovation not with costly hardware retrofits but with simple isoftware upgrades.
The Step-Change that demonstrates the trend: Gingko’s BioWorks2
A step change in that transition arrived this morning with news that Ginkgo BioWorks announced the launch of their next generation foundry, Bioworks2. With t25,000 square feet and at least 6X expected increase in capacity compatred to BioWorks 1, Bioworks2 represents a step change in what is possible for organism design. The company, which has raised a monstrous amount of money in the past 18 months, is strategically focused on using biology to make an impact in markets including flavors and fragrance, cosmetics and personal care, and food and nutrition.
Gingko's BioWorks1 facility
Gingko’s BioWorks1 facility
“Ginkgo’s foundries bring tremendous capability to accelerate organism engineering and complement our strengths in whole-process design, computation, and manufacturing scale-up,” said Christophe Schilling, CEO of Genomatica.
As Gingko itself notes, “biology is the most advanced manufacturing technology on the planet. Self-assembling, self-replicating, and self-repairing, biology builds renewably—from the molecular machines inside of cells to global ecosystems.
What is a bio-foundry?
In biological engineering, living organisms are the factories that build new products. Designing the best organisms requires a different sort of factory, one where the best tools in automation, analytics, and software can all work in sync. Bioworks1 was the world’s first organism foundry, where engineers are prototyping thousands of biological designs.
And so, Ginkgo Bioworks designs custom microbes for customers across multiple markets. The foundries are used to scale the process of organism engineering using software and hardware automation.
A new alliance with Genomatica
Also this week, Ginkgo Bioworks and Genomatica have allied to more rapidly deliver biology-based solutions for the world’s highest-volume intermediate and specialty chemicals.
The alliance aims to accelerate the transition of the mainstream chemical industry to biological process technology. Bio-based production of intermediate chemicals can deliver better overall economics and greater sustainability and performance by harnessing the power of biotechnology and microorganism engineering to grow products. Only a few dozen chemicals at the heart of the mainstream industry, with markets up to millions of tons and many billions of dollars each, are used to make the thousands of everyday products that fill our homes, stores and offices. Bringing together a full stack of best-in-class capabilities with clear industry leadership, the alliance provides a compelling new reason for mainstream chemical firms to explore and adopt these new biological technologies.
“The combination of our technologies will allow us to more rapidly extend the benefits of biotech into many high-volume markets,” said Jason Kelly, CEO, Ginkgo Bioworks. “Genomatica is the perfect ally to help bring the power of our foundries to mainstream chemical markets. Genomatica is proven at high-yield bio-based processes, which is essential for widespread deployment of cost-effective technology to produce major-market chemicals.”
Mainstream chemical producers can now in-license technology to manufacture their widely-used chemicals with cost-effective and sustainable whole-process solutions that include engineered microorganisms, complete process designs and technology transfer support. The alliance is structured as a deep collaboration, with two-way sharing of technology and intellectual property, along with joint technology development, to provide a single unified offering to the market.
“This alliance should be a welcome and familiar approach to anyone in the chemical industry,” said Carlos A. Cabrera, Executive Chairman, Genomatica, and the former CEO of UOP. “The potential of biology to impact our industry is substantial and rapidly evolving. Genomatica and Ginkgo now make it practical and feasible for existing and new industry participants to access, license, and deploy cost effective and innovative biotechnology.”
Gingko’s strattegic partnership with Amyris
In June, Amyris entered into an Initial Strategic Partnership Agreement with Ginkgo Bioworks to accelerate commercialization of bio-based ingredients and establish clear leadership in industrial biotechnology with a combined offering. As part of the deal, Ginkgo Bioworks will expand Amyris’ strain engineering capability via access to its world-class foundry; Amyris will be responsible for bringing products to scale. Together, the two companies have a portfolio of more than 70 products under contract for delivery to the world’s leading brands across industrial, health and personal care markets. Together, the two companies expect to deliver more than 20 new products over the next three years.
The Bottom Line
A journey of a hundred years begins with a handful of steps — the steps we see companies like Gingko, Amyris, Genomatica and others such as Zymergen, Caribou Biosystems, Gen9, and Arzeda are taking this year.
Look a little down the road beyond the innovations of today, and imagine the logical consequence.
Today, our intelligence allows us to parrot and manipulate an organism with the complexity of a microbe. Eventually, we will have the sophistication to design, build and operate factories that work like animals — complex worls of inputs, outputs, sensors, barriers, analytics, waste recovery, separation, and dare we say intelligence. When the factory and the animal converge, you will know that we are there.
Notice AMRS name in this
Growing Energy Deficit Will Encourage Economies to Invest in Bioenergy Plants, says TMR
Press release from: TMR - Research Reports
The competition in the bioenergy market is being driven by the domination of big players who are adopting innovative strategies to increase their geographical research, finds a new report by Transparency Market Research.
Currently, large companies, such as E. I. du Pont de Numerous and Company, are focusing on establishing its presence in various regions and on strengthening their vertical integration activities by offering a wide range of products that are used for making advanced biofuels, thereby winning business from other operating players. Additionally, companies are also spending a significant amount of their budget on creating brand awareness, which can be seen in the business strategy of companies such as Amyris Inc’s, notes TMR.
Add a little spice
One of the first things that we learn as investors is that the news moves the market. In this particular case, the news was overwhelmingly positive. So, it's only natural that we're seeing a positive reaction in the market. Currently (11:26), AMRS is trading at $0.57 per share after a gain of $0.06 per share (12.61%) thus far today.
Or this news brief..
Amyris Inc
* Expanded its strategic partnership with a "global nutraceuticals market leader"
* New agreement includes addition of a new nutraceutical target, a credit line of up to $25 million with a 5-year maturity
* Says anticipated revenues from expanded partnership are expected to average over $70 million annually beyond 2017
* New agreement includes an option for a $5-million strategic investment Source text for Eikon: Further company coverage:
Oh...or this one
myris, Inc. (Nasdaq: AMRS), the industrial bioscience company, today announced that it has expanded its strategic partnership with a global nutraceuticals market leader. The new agreement represents a significant expansion in expected revenue compared to the prior agreement announced on April 27, 2016, and includes the addition of a new nutraceutical target, a credit line of up to $25 million with a 5-year maturity, and an option for a $5-million strategic investment from one of the world’s leading nutraceuticals manufacturers.
Amyris has already started large shipments of farnesene as part of its earlier announced supply agreement with this partner, for which Amyris has become an essential part of its highly disruptive technology to capture market share. The partner is nearing completion of a dedicated manufacturing facility to convert Amyris’s farnesene and expand volume production over time.
This agreement and the related processing technology for the farnesene building block will enable a significant cost advantage within a large global market for what will now be two agreed on global products used daily by many for nutritional benefit. This is a significant achievement consistent with Amyris’s mission to help its customers do better while doing better for the planet. Demand for global nutritional products continues to grow at a much faster pace than GDP and supplying these products from sustainable sources at a lower cost than currently possible is critical for the growing population of the world.
Amyris now expects 2017 revenue for the first targeted product of around $40 million and anticipated revenues from the expanded partnership are expected to average over $70 million annually beyond 2017. This expansion is expected to lead to the second molecule to be supplied by Amyris in 2019 into a market that is approximately the same size as the first agreement. These agreements demonstrate the leadership position of Amyris as the only company in industrial biotechnology to produce multiple molecules at a single industrial fermentation facility and with one of the strongest contracted product pipelines in the sector.
Due to the competitive nature of this market both parties have agreed to keep the targeted products and the customer’s name confidential. The expansion of the partnership is subject to obtaining required approvals.
“We’re very pleased with our achievement to date and the significant expansion of our partnership. This relationship continues to be based on our ability to provide our partners with low-cost, high-performance farnesene that can provide them with a competitive advantage while enabling them to grow sustainably,” said John Melo, President & CEO of Amyris. “This expanded partnership agreement further transitions us to a more broadly diversified portfolio of high performance, sustainable ingredients to some of the world’s fastest-growing markets and a global leader in low cost, high performance ingredients for the nutraceuticals market.”
So....how do you like that one
Feast on this one...I knew articles would begin to come out after that news release so here you go
Amyris Inc (NASDAQ:AMRS) is having an incredible day in the market today, and for good reason. Early this morning, the company announced that a strategic partnership has been expanded. This expansion comes with the expectation of increased revenue. Today, we’ll talk about the news, what we’re seeing in the market as a result, and what we can expect to see from ARMS moving forward.
AMRS Gains On Extended Collaboration
As mentioned above, Amyris Inc (NASDAQ:AMRS) is having a strong day in the market today after announcing that it has made the decision to extend its partnership with a global nutraceuticals market leader. This new agreement is an expansion on an older agreement that was announced to the public on April 27th. Under the agreement, there are new nutraceutical targets. On top of that, a credit line of up to $25 million with a 5-year maturity, and an option for a $5 million strategic investment from one of the leaders in nutraceuticals is also included in the deal.
The client that AMRS has expanded its agreement with has already accepted farnesene as part of the earlier announced supply agreement. In fact, in today’s announcement, we learned that the company has become an essential part of the nutraceutical leaders’ highly disruptive technology to take control of a larger market share. It was also announced that the undisclosed partner is nearing completion of a dedicated manufacturing facility. The goal at this facility is to convert farnesene and expand volume production over time.
What About The Money?
This is a great deal for Amyris Inc (NASDAQ:AMRS) when it comes to potential earnings. In fact, the company expects that 2017 revenue from the first target product in this relationship to come in around $40 million. After 2017, it’s expected that the company will bring in about $70 million a year as a result of the partnership. In a recent statement, John Melo, President & CEO at Amyris had the following to offer:
“We’re very pleased with our achievement to date and the significant expansion of our partnership. This relationship continues to be based on our ability to provide our partners with low-cost, high-performance farnesene that can provide them with a competitive advantage while enabling them to grow sustainably… This extended partnership agreement further transitions us to a more broadly diversified portfolio of high performance, sustainable ingredients to some of the world’s fastest-growing markets and a global leader in low cost, high performance ingredients for the neutraceuticals market.”
How The Stock Is Reacting To The News
One of the first things that we learn as investors is that the news moves the market. In this particular case, the news was overwhelmingly positive. So, it’s only natural that we’re seeing a positive reaction in the market. Currently (11:26), AMRS is trading at $0.57 per share after a gain of $0.06 per share or 12.61% thus far today.
What We Can Expect To See Moving Forward
Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from Amyris Inc (NASDAQ:AMRS). This year has been an incredible one for the company as it has launched several new collaborations that will likely drive strong revenue in the long run. Today’s agreement further validates the idea that the company is slated for growth. Considering the strong year of collaborations, the product, and the management’s ability to grow this business, I’m expecting to see gains in AMRS ahead.
Great day today...now let it go into after-hours and premarket Monday morning...looking for 1.00
REMEMBER... .60 is pocket change to what AMRS is going to be trading at...man, do your own DD....imo
These opportunities come along only ever so often...i told you yesterday just wait until the next good news release and how I saw nothing but good things from now through 2017, with 2017 being even a stronger stock...
Well guys I got one of those stocks---AMRS imo
Note: AMRS is not a "ONE DAY WONDER" AMRS is for REAL
All these compannies doesnt put up this kind of money for that
Watch as we move toward 1.00
After a weekend when news gets out and with new articles written its just what I see
I expect SEEKING ALPHA to really come out strong as well as others
Dont be surprised to see some new analyst begin to initiate coverage on ARMS
Again this is not a "flash in the pan" nor a 'one day wonder"
AMRS is not like other stocks in this range...AMRS is not a joke
Just dont think anything can keep us back...moving toward 1.00
Looking for 1.00 and over now guys...all the pieces are there...AMRS just keeps getting better and better...they are in a great position
Expect the next SEEKING ALPHA article to go PARABOLIC...this stock is a winner...and these do not come around often....wow
Just watch now when analyst see this....this will get their attention
previous SEEKING ALPHA articles where 100% correct...and this is HUGE for what it means in support of AMRS...just WOW
AMRS is blowing the doors off...for 2nd half and 2017...
HUGE indeed...bigtime
Wow....lets see what happens when analyst gets ahold of this news...wow
Yes, AMRS is a no trainer..some day trade, some swing trade, some may actually hold long..I will probably buy again tomorrow....AMRS ISNT GOING AWAY....wait for the next news..this is no flash in the pan...tooooo many BIG players in AMRS...deal with it......
If the US Department of Defense gave AMRS 34 Million how much do you think any deals with BIOGEN...JNN...Gingko...Givaudan would be worth....then AMRS gets on the BUYOUT SCREENS....millions and millions and millions of dollars with any of those mentioned above....next news release will get here...just waiting.....HAVE A GREAT DAY...look for a leg up toward ...57/.60 toward the close today...AMRS has so many things going for it....ITS A NO BRAINER FOR ME..............IMO
B-I-O-G-E-N, JNJ, US Defense Dept, Gingko, Givaudan.....
Plus
John Doerr is widely regarded as one of the most successful venture capitalists ever. He was one of the first investors in both(!) Google (NASDAQ:GOOG) (NASDAQ:GOOGL) and Amazon (NASDAQ:AMZN). He serves as a board member for both Google and Amyris.
John Doerr recently bought $25 million worth of Amyris stock for himself at a price of over $1.5 per share (source). Today, you can get a share for $0.4. Surely, it might be worth to take a look at Amyris.
D-E-A-L with that.....................................................................................................................................................................................................................Yes we have a winner.....IMO...watch it rise
I think in one of "myopinion" post he said he expected
.56 by today....we may close near or over that by the close....
When good news comes out I expect it to propel us to 1.00 or over...
one writer said he expected it to double and triple ....I do to
I post this again...and I did not write this
Amyris has been on a tear lately. Its shares have gained over 30% in the last two week on ever increasing trading volumes. This trend is expected to continue.
Recent positive news about major partnerships with industry leaders in various markets suggest that the blockbuster potential with this industry leader is finally about to unfold.
Amyris has grown sales of its own products at double-digit rates for the last three quarters. This trend is expected to continue as the company keeps developing award-winning products.
As I see it AMRS has all the huge potential analyst have said...Biogen, Ginkgo, The US Government and others have already said and are at work on...
But hey, you dont have to believe it...But if it sitting over 1.00 and you didnt believe it then you have no one to blame but yourself...AMRS at these prices and potential only come around ever so often....the material is all there just do your own DD
I believe I read in one of the releases that AMRS was going to be using those labs...I believe that is correct...it was an advantage for AMRS saving them cash by providing AMRS with the facilities and I am sure the cost is paid to Ginkgo by licensing ect...its like AMRS has the code and there are sooooo much potential for sooooo many new items I cant even fathom right now....but evidently Biogen Ginkgo and the others do and are making their facilities available to AMRS......
a few years ago i missed out on a stock big time....it had fallen to .88 per share...i bought some and sold around 1.40....the stock went to over 26.00 per share and today sits at almost 18.00..i havent forgot it....i still feel the pains of it today....recently bought one at around 1.10 and sold it around 1.44...right now it is at 1.78
I think AMRS can move bigtime...well over 1.00...just watch for a good news release and watch it....
if we get another good news release AMRS will move big...imo
I did not write those articles we have been posting...so others who know more than me write them.....huge potential...
I await good news and the move out of this territory
i know how it feels to get left behind...you feel bad when you let one get by you....60/.70/80 to 1.00 and above if they continue as they are
oh yes...maybe very early today
see if you hit .545/.55 early....watching for the support and break above .55///watching for the continued support
do you know this guy
I will leave you with this - John Doerr is widely regarded as one of the most successful venture capitalists ever. He was one of the first investors in both(!) Google (NASDAQ:GOOG) (NASDAQ:GOOGL) and Amazon (NASDAQ:AMZN). He serves as a board member for both Google and Amyris.
John Doerr recently bought $25 million worth of Amyris stock for himself at a price of over $1.5 per share (source). Today, you can get a share for $0.4. Surely, it might be worth to take a look at Amyris.
Please let me help you
Having largely divested its fuels business, the company now focuses on higher margin products. It produces molecules for fragrances and cosmetics, nutraceuticals, drugs, tire rubber and more. Their current gross margin is over 58% (source). Moreover, they are experiencing huge product sales growth. In the past two quarters, Amyris achieved product sales growth of over 45%, after having double-digit growth rates for the prior three quarters. In Q2 2016, product sales reached $4.9M, while total revenue was at $9.6M (source).
Amyris is still making large capital investments, which sales revenue alone cannot cover. To that end, it does collaborative research projects where large corporate partners give Amyris cash to do research work to figure out the feasibility of producing certain molecules. If the studies succeed, Amyris also gets to produce those molecules and earn more money that way. Recent collaborations include those with Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ) and Cathay Pacific (owned by Swire (HKG:0019)) (source). In effect, Amyris's customers are sponsoring R&D work for the company.
Finally, Amyris gets grants from the US Government for research purposes. Recently, the Department of Energy gave Amyris a multimillion-dollar grant for research into biofuels (source). More importantly, DARPA, the Pentagon's research arm, gave Amyris a $34 million grant to create technologies to develop new molecules and bring them to market faster (source). Under the terms of the agreement, Amyris gets to keep the IP for all new molecules developed in this program.
The long-term potential of the company is enormous. The competitive advantage of the company can roughly be divided into two parts.
Can you handle the following
AMRS 50c I Expect A Double And Even A Triple This Year. Long-Term Potential Is $10 And More 3 comments
Sep 21, 2016 4:01 AM
Summary
Amyris has been on a tear lately. Its shares have gained over 30% in the last two week on ever increasing trading volumes. This trend is expected to continue.
Recent positive news about major partnerships with industry leaders in various markets suggest that the blockbuster potential with this industry leader is finally about to unfold.
Amyris has grown sales of its own products at double-digit rates for the last three quarters. This trend is expected to continue as the company keeps developing award-winning products.
AMRS expects to end the year with a stronger balance sheet due to upcoming no-core sales and debt-reduction initiatives. The company expects to make announcements shortly according to a recent investor's presentation.
The company expects to report record 3Q and 4Q revenues and forecasts ending the year on cash-flow positive status for the first time in company history according to its most recent press release.
It isn't everyday you get a stock like this...no wonder they put those price targets on like that....because they are supposed to post 80 million or more the the 2nd half of 2016.... don't expect it to be at this price very long..maybe not another day...imo
Be interesting to see where we open in the morning...got great support....looking for .60??
Oh I see...that is after their presentation....great